Waqar Saiama N, Morgensztern Daniel
Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Expert Rev Clin Immunol. 2015;11(8):871-3. doi: 10.1586/1744666X.2015.1054374. Epub 2015 Jun 7.
In this editorial, we highlight the exciting advances in immunotherapy for the treatment of non-small cell lung cancer, with nivolumab being the first immunotherapeutic agent to be approved by the US FDA for the treatment of squamous lung cancer and several other promising immune checkpoint inhibitors currently being evaluated in clinical trials. The next step is to understand the mechanisms of resistance and develop rational combinations in an attempt to further improve the responses and survival in lung cancer.
在这篇社论中，我们重点介绍了免疫疗法在非小细胞肺癌治疗方面取得的令人振奋的进展，纳武单抗是首个获美国食品药品监督管理局批准用于治疗肺鳞癌的免疫治疗药物，目前还有其他几种有前景的免疫检查点抑制剂正在临床试验中接受评估。下一步是了解耐药机制并制定合理的联合用药方案，以期进一步提高肺癌治疗的缓解率和患者生存率。
